Lentini P, Zanoli L, Ronco C, Benedetti C, Previti A, Laudadio G, Vienna F, Andrighetto S, Fuso V, Gambaro G. The Vascular Disease of Diabetic Kidney Disease.
Cardiorenal Med 2022;
13:202-210. [PMID:
36279858 DOI:
10.1159/000527274]
[Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/18/2022] [Accepted: 09/23/2022] [Indexed: 12/22/2023] Open
Abstract
BACKGROUND
The incidence of cardiovascular disease (CVD) is increased in patients with diabetic kidney disease (DKD).
SUMMARY
Aortic stiffness is a well-accepted biomarker for cardiovascular (CV) events in all stages of CKD. The worldwide prevalence of diabetes continues to grow, as does the prevalence of DKD. Insulin resistance, hyperglycaemia, hypertension, and the metabolic abnormalities of type-2 diabetes are all involved in the pathogenesis of CVD. The effect of these toxins on cardiac and vascular function is amplified by the worsening of renal function and the parallel rise of uraemic toxins.
KEY MESSAGES
In this narrative review, we analysed why arterial stiffening can be considered a vascular mediator between diabetes and cardiac dysfunction, and we discussed the strong CV and nephroprotective effects of sodium-glucose cotransporter type-2 inhibitors.
Collapse